Cellular Therapy
Conference Coverage
Using engineered T cells reduced acute, chronic GVHD
Conference Coverage
Novel ddPCR assay precisely measures CAR T-cells after infusion
Conference Coverage
CAR T-cell products shine in real-world setting, reveal new insights
Real-world CAR-T experience provides new insights for predicting outcomes in patients with DLBCL.
Video
Experts break down latest CAR T-cell advances in lymphoma
ORLANDO – An expert panel of physicians discusses the latest research on CAR T-cell therapy in lymphoma, presented at the 2019 annual meeting of...
From the Journals
CAR T-cell therapy may worsen mental health in some patients
From the Journals
Several factors may drive recent improvements in allo-HCT outcomes
Patients transplanted in recent years were older and sicker at baseline but had better outcomes than did patients transplanted in the mid-2000s....
From the Journals
New toxicity subscale measures QOL in cancer patients on checkpoint inhibitors
With further validation, the instrument could become an important tool for evaluation of treatment-related toxicity.
Conference Coverage
CAR T cells produce complete responses in T-cell malignancies
ORLANDO – There were no cases of severe cytokine release syndrome or severe neurotoxicity reported with the anti-CD5 chimeric antigen receptor T...
Conference Coverage
CAR T-cell therapy advances in CLL
ORLANDO – The safety and clinical activity of the CD19-directed CAR T-cell agent justifies moving forward with phase 2 investigation, researchers...
Conference Coverage
Inhibitor appears to strengthen anti-BCMA CAR T cells in myeloma patients
ORLANDO – All 10 patients responded to anti-BCMA CAR T-cell therapy, including 3 patients who had previously failed BCMA-directed therapy.
Conference Coverage
‘Real-world’ data show CAR T therapies are cost effective
ORLANDO – An analysis of Medicare claims data found that treatment with CAR T-cell therapy was associated with fewer hospitalizations and shorter...